Adipose derived stem cells (ADSCs) are stem cells derived from adipocytes, and can differentiate into variety of cell types. ADSCs have multipotency similar to bone marrow mesenchymal stem cells, thus ADSCs substitute for bone marrow as a source of stem cells. Numerous manual and automatic stem cell separation procedures are adopted in order to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can also be used to isolate ADSCs from other stem cells within a cell solution.
Adipose derived stem cells are gaining appeal as a new cell source in regenerative medicine therapies as it can be differentiated into a variety of different cell lineages. These stem cells also have anti-apoptotic, anti-inflammatory, pro-angiogenic, immunomodulatory, and anti-scarring properties, which enhances its effectiveness.
Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2357
High effectiveness of adipose derived stem cell therapy in various medical and biotechnology research fields coupled with growing research and development activities by various research organizations is expected to boost the adoption of adipose-derived stem cell therapy in the market during the forecast period. Adipose derived stem cells (ADSCs) have various applications in medical and biomedical science field such as treatment of diabetes; regeneration of tissues partially in osteogenic, adipogenic, chondrogenic, and cardiovascular areas of medicine; bone regeneration; fat reconstruction; and myocardial and cardiovascular regeneration; among others.
For instance, in November 2018, a peer-reviewed case study conducted using a stem cell processed by Celltex Therapeutics Corporation, showed the improvement in disease findings following systemic administration of autologous adipose derived mesenchymal stem cells (MSCs).
Market Regional Analysis
North America is expected to hold a dominant position in the global adipose derived stem cell therapy market and account the largest market share during the forecast period, owing to high presence of key players in the region, which are engaged in research & development activities and implementing in-organic growth strategies such as acquisition and collaboration to increase its market presence.
For instance, in December 2017, Mesoblast Limited made exclusive license agreement with TiGenix NV, through which Mesoblast granted TiGenix an exclusive access to certain of its patents to support global commercialization of Cx601, adipose derived mesenchymal stem cell product, for the local treatment of fistulae.
Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2357
Market Restraint –
High cost associated with stem cell processing, need of skilled professional for managing, preserving, and scale-up of stem cell lines are the limiting factors, which are expected to restrain the growth of the adipose derived stem cell therapy market during the forecast period.
For instance, Bioinformant— a research firm engaged in stem cell research— released a data on November 2018, on cost of stem cell therapy and various key factors impacting the cost of stem cell therapy including types of stem cells used within procedure, number of treatment, and the site of the clinic. The study findings reveal the cost of stem cell therapy ranges between US$ 5,000-8,000 per patient, in some cases it may rise as much as US$ 25,000 or more depending on the complexity of the procedure.
Market Key Players –
Key players operating in the global adipose derived stem cell therapy market include BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.
Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/2357